Experts break down the most important facts about atopic dermatitis on the hands, including risk factors, treatments, and tips for soothing relief. Atopic dermatitis (AD), the most common form of ...

Please provide your email address to receive an email when new articles are posted on . The updated label shows safety and efficacy in treating moderate to severe atopic dermatitis of the hands or ...

Please provide your email address to receive an email when new articles are posted on . 40% to 50% of patients with chronic hand eczema have concomitant atopic dermatitis. Differentially expressed ...

Findings showed 40% of patients treated with dupilumab achieved an IGA score of 0 (clear) or 1 (almost clear) on the hands and feet at week 16, compared with 17% of those who received placebo. The ...

A wearable sensor that sticks onto the back of the hand and uses an artificial intelligence (AI) algorithm to monitor scratching activity when the wearer sleeps has been shown to reduce subconscious ...

If you experience chronic dry, itchy and red skin, you may be one of the millions of Americans with eczema. The National Eczema Association reports that an estimated 10% of the world population ...

A deeper understanding of chronic hand eczema (CHE) -- its pathogenesis, clinical subtypes and presentation, and risk factors -- would help expedite quicker diagnosis and appropriate care. That's the ...

If you have atopic dermatitis (AD), also known as eczema, then you know the struggle: You climb into bed ready to catch some zzz's, but can't sleep because of the intense, relentless itching. Thanks ...

AMSTERDAM — The Janus kinase inhibitor delgocitinib may be a better or comparable choice for treating hand eczema than some more established therapies, suggested the results of two separate studies ...

Also called eczema, atopic dermatitis is estimated to affect 10 to 20 percent of children, usually babies or very young kids, although it can last past adolescence and into adulthood. The skin ...

An artificial intelligence (AI)-enabled hand sensor delivering closed-loop haptic feedback appeared to be an effective nonpharmacologic intervention to decrease nocturnal scratching in patients with ...

The MarketWatch News Department was not involved in the creation of this content. -- ADHAND is a phase 3b placebo-controlled clinical trial evaluating the efficacy and safety of tralokinumab in adult ...